Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
Linking Haplotypes and Genetic Variation with Cancer Risk Assessment, Prevention, Detection and Treatment Workshop

Agenda

Thursday, December 04, 2003
7:00 amRegistration and Continental Breakfast
8:30 amWelcome RemarksPeter Greenwald
Edward Trapido
8:40 amCharge to ParticipantsWendy Wang
8:50 amKeynote Address: How To Use Haplotypes To Find Disease Genes and Predict Individual Risk Francis Collins
9:50 amBreak
10:00 am - 12:00 noon Session 1: The Human HapMap and Other Haplotype Studies: Definition, Background, and Current Status
Chair: Francis Collins
10:00 - 11:30 am Patterns of Human VariationLynn Jorde
The International HapMap ProjectStacey Gabriel
Haplotypes and Linkage Disequilibrium: Disease Gene Discovery Cheryl Winkler
Stephen O'Brien
Strategies To Select Haplotypes: Link to Disease and Cancer Stephen Chanock
11:30 am

Discussion
Discussion Moderator: Joel Hirschhorn
Discussion Panel: Lisa Brooks, Stephen Chanock, Francis Collins, Nancy Cox, Matt Freedman, Stacey Gabriel, Lynn Jorde, and Cheryl Winkler

  • Discussion topics for Session 1 include these questions:
  • What are the status and plans for the human haplotype map (HapMap)?
  • What is the relationship between haplotypes and SNPs (Single Nucleotide Polymorphisms) and their advantages and disadvantages as genetic markers for cancer prevention studies?
  • What are definitions of haplotype blocks?
  • What is the vision for the use of the HapMap?
  • How can cancer prevention researchers use the HapMap information?
12:00 noonLunch
1:00 - 2:30 pm Session 2: Studies of Haplotypes and Cancer in Populations: Genetic and Molecular Epidemiology and Risk Assessment
Chair: Timothy Rebbeck
1:00 - 2:30 pm Haplotype Association and Haplotype-Sharing Methods: Study Design, and Analysis Consideration Duncan Thomas
Family-Based Designs for Haplotype Studies of Cancer Risk Daniel Schaid
Haplotype Studies of Breast and Prostate Cancer in the Cohort Consortium David Hunter
Current Status and Needs of Haplotype-Based Cancer Research in Human Populations Timothy Rebbeck
2:30 pm

Discussion
Discussion Moderator: Christopher Amos
Discussion Panel: Steve Chanuck, Dan Cramer, David Hunter, Timothy Rebbeck, Nathaniel Rothman, Daniel Schaid, Daniela Seminara, Peter Shields, Duncan Thomas, Wendy Wang, Qingyi Wei, Debbie Winn, and Xifeng Wu

  • Discussion topics for Session 2 include these questions:
  • Use of haplotypes and SNPs in studies of cancer gene identification, characterization and GxG and GxE interactions: What do we know and what do we need to learn?
  • What are the most appropriate study designs and analytic approaches?
  • What are the haplotype-related informatics needs?
  • What studies are needed to determine the functional relevance of haplotypes?
  • What are currently available high throughput genotyping platforms? How can these technologies be incorporated most efficiently in genetic and molecular epidemiology studies using SNPs and haplotypes?
  • What infrastructures are needed to support haplotype-based studies of cancer in human populations?
3:00 pmBreak
3:15 - 5:30 pm Session 3: New Directions for the Applications of Haplotypes in Cancer Prevention and Treatment
Chair: Peter Greenwald
3:15 - 4:30 pmHaplotypes and Colon CancerSteve Gruber
Gad Rennert
Trials for Prostate Cancer PreventionIan Thompson
Estrogen Sulfation: Intragene Haplotypes and Risk Richard Weinshilboum
SNPs, Haplotypes, and FunctionsJuergen Reichardt
4:30 pm

Discussion
Discussion Moderator: Charis Eng
Discussion Panel: Dean Brenner, Dan Cramer, Steve Gruber, Gad Rennert, David Hunter, Juergen Reichardt, Sudhir Srivastava, Ian Thompson, Wendy Wang, Qingyi Wei, Richard Weinshilboum and Xifeng Wu

  • Discussion topics for Session 3 include these questions:
  • What are examples of the use of haplotypes and genetic variation in prevention and treatment?
  • Why and how can SNPs and haplotypes be used in clinical trials?
  • Which currently available prevention trial cohorts/populations could be used for haplotype-relevant studies?
  • How could haplotypes be used to design therapies?
5:30 pmAdjourn

Thursday, December 05, 2003
Chairs: David Sidransky and Charis Eng
8:30 amKeynote Address:
Biomarker-based Lung Cancer
Prevention Trial in Former Smokers:
Evidence of Interactions between Retinoid Nuclear Receptor and DNA Repair Pathways		 Waun Ki Hong
Jonathan Kurie
Qingyi Wei
9:10 amHaplotypes and Rare CancerCharis Eng
9:30 amGenetic Association Studies of Breast and Prostate CancerMatt Freedman
9:50 - 10:00 amCoffee Break
10:00 amReport from session 1: Summary and next steps
10:30 amReport from session 2: Summary and next steps
11:00 amReport from session 3: Summary and next steps
11:30 amDiscussions: Future Directions for Using Haplotypes for Prevention, Detection, and Treatment
Discussion Moderators: David Sidransky and Charis Eng
Discussion Panel: Dean Brenner, Matt Freedman, Li Jin, Jonathan Kurie, Timothy Rebbeck, Cheryl Winkler, Daniela Seminara, and Mukesh Verma
12:30 pmAdjourn


Back to top